title: Glucagon-like peptide-1 analogue LY315902: effect on intestinal motility and release of insulin and somatostatin.
abstract: LY315902 is an analogue of GLP-1 that yields a reduced clearance and longer half-life. The aim of the study is to assess the effect of LY315902 on fasting gastrointestinal motility, somatostatin and insulin release. Sprague-Dawley rats were fitted with three bipolar electrodes, 15, 25 and 35 cm distal to the pylorus. The effect of LY315902 and GLP-1 on migrating myoelectric complex (MMC) cycle length, duration and propagating velocity of activity fronts was studied for 60 min in conscious animals. The effect of LY315902 and GLP-1 on fasting small bowel motility was dose-dependent and treatment with exendin (9-39)amide, a GLP-1 receptor antagonist, together with LY315902 and GLP-1 completely antagonised the inhibitory effect of LY315902 and GLP-1 on fasting small bowel motility. Pretreatment with the nitric oxide (NO) synthase inhibitor N(omega)-nitro-L-arginine (L-NNA) partly blocked the action of both LY315902 and GLP-1. Plasma insulin concentrations were not different from controls during infusion of LY315902 or GLP-1, while somatostatin concentrations were significantly higher during LY315902 and GLP-1 compared to saline. LY315902 has a longer duration of inhibitory action on the MMC than GLP-1, albeit similar effects on plasma insulin and somatostatin concentrations. The effect of LY315902 on motor control is mediated through the GLP-1 receptor and seems partly dependent on the L-arginine/NO pathway.
authors.affiliation: Division of Surgery, Karolinska Institutet Danderyd Hospital, SE-182 88 Danderyd, Stockholm, Sweden. Erik.Naslund@kir.ds.sll.se
authors.forename: Erik
authors.initials: E
authors.lastname: Näslund
authors.forename: Staffan
authors.initials: S
authors.lastname: Skogar
authors.forename: Suad
authors.initials: S
authors.lastname: Efendic
authors.forename: Per M
authors.initials: PM
authors.lastname: Hellström
mesh_terms: D000818:Animals; D005215:Fasting / Q000502:physiology; D005769:Gastrointestinal Motility / Q000187:drug effects*; D005934:Glucagon / Q000494:pharmacology; D052216:Glucagon-Like Peptide 1; D007328:Insulin / Q000097:blood / Q000378:metabolism*; D000078790:Insulin Secretion; D008297:Male; D010446:Peptide Fragments / Q000494:pharmacology; D010455:Peptides / Q000008:administration & dosage / Q000494:pharmacology*; D011498:Protein Precursors / Q000494:pharmacology; D051381:Rats; D017207:Rats, Sprague-Dawley; D013004:Somatostatin / Q000097:blood / Q000378:metabolism*
chemical_list: D007328:Insulin; C107458:LY 315902; D010446:Peptide Fragments; D010455:Peptides; D011498:Protein Precursors; D013004:Somatostatin; D052216:Glucagon-Like Peptide 1; D005934:Glucagon